A framework for organizing and scoring diabetes research evidence. Explore evidence topics, study relationships, and validated research signals.
Early access — Evidence base actively growing
Last updated: 7/15/2026
Start here to explore the most useful evidence topics.
What helps lower HbA1c in diabetes?
What helps with weight loss in diabetes?
What improves glycemic control in diabetes?
What improves insulin resistance in diabetes?
What helps with prediabetes?
What helps diabetic kidney disease?
Recent research signals, evidence movement, and emerging areas worth watching.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Strongest evidence in the database
This relationship has 11 studies with strong evidence, representing the most robust finding in our evidence base.
Evidence trends, state changes, and momentum history will activate once monthly snapshots accumulate. Requires at least two monthly evidence snapshots. Temporal intelligence will activate once historical data accumulates.
Find evidence by the outcome people are trying to improve.
Evidence related to lowering or improving HbA1c/A1C in diabetes management.
Evidence related to body weight reduction, BMI improvement, waist circumference, and body composition changes.
Evidence related to blood glucose control, fasting glucose, postprandial glucose, glucose variability, and time in range.
Evidence related to blood pressure, lipid profile, cardiovascular risk, cardiovascular events, and cardiometabolic risk markers in diabetes.
Evidence related to treatment adherence, medication use, physical activity participation, step count, diet intake, fruit and vegetable intake, and...
Evidence related to physical activity levels and physical activity changes in diabetes studies.
Find evidence by treatment category, care approach, or lifestyle strategy.
Evidence related to continuous glucose monitoring, insulin pumps, hybrid closed-loop systems, telemonitoring, mobile apps, digital health programs,...
Evidence related to DSMES, diabetes education, self-management programs, case management, remote education, knowledge, adherence, and self-care beh...
Evidence related to dietary patterns and nutrition strategies for diabetes, including low-carbohydrate, Mediterranean, ketogenic, low-glycemic-inde...
Evidence related to vitamins, minerals, probiotics, synbiotics, botanicals, and nutraceutical supplements studied in diabetes.
Evidence related to metformin therapies in diabetes studies.
Evidence related to GLP-1 receptor agonist therapies in diabetes studies.
Evidence related to liraglutide and liraglutide-containing intervention regimens in diabetes studies.
Evidence related to insulin therapies in diabetes studies.
Evidence related to SGLT2 inhibitor therapies in diabetes studies.
Evidence related to DPP-4 inhibitor therapies in diabetes studies.
Evidence related to diabetes self-management education and support programs in diabetes studies.
Evidence related to aerobic exercise interventions in diabetes studies.
Evidence related to probiotic and synbiotic interventions in diabetes studies.
Evidence related to alpha-glucosidase inhibitor therapies in diabetes studies.
Find evidence by diabetes-related conditions, risks, or complications.
Evidence related to improving insulin resistance, insulin sensitivity, fasting insulin, C-peptide levels, and beta-cell function in diabetes and pr...
Evidence related to preventing or delaying type 2 diabetes, reducing diabetes incidence, and improving metabolic risk in people with prediabetes.
Evidence related to diabetic kidney disease, albuminuria, kidney function, nephropathy progression, end-stage renal disease, and kidney-protective...
Evidence related to diabetic neuropathy incidence, neuropathy progression, neuropathic pain, balance, mobility, and interventions studied for nerve...
Evidence related to diabetic retinopathy incidence, retinopathy progression, microvascular complications, and diabetes interventions studied for ey...
Evidence related to hypoglycemia events, severe hypoglycemia, time below range, postprandial hypoglycemia, symptom recognition, and diabetes interv...
Evidence related to cardiovascular risk, cardiovascular events, ASCVD risk, vascular function, functional capacity, and mortality outcomes in diabe...
Focused measurement and research-area topics.
Evidence related to inflammatory, oxidative stress, endothelial, and vascular biomarkers measured in diabetes studies.
Evidence related to adverse events, serious safety outcomes, gastrointestinal events, urinary tract infections, DKA, hyperglycemia, and treatment t...
Metformin Therapies → HbA1c
Peer-reviewed studies in evidence base
Relationships with strong or very strong ratings
GLP-1 Receptor Agonists → Neuropathy
Intervention-outcome combinations
Diabetes Self-Management Education and Support (DSMES) Programs → HbA1c
Intervention-outcome relationships with the strongest evidence validation and replication
| Intervention | Outcome | Details | EvidenceScore™ | ImpactScore™ | Consistency | Studies | Action |
|---|---|---|---|---|---|---|---|
| Metformin Therapies | HbA1c | 88/100Strong | 83/100Positive | 86/100consistent | 8 | ||
| GLP-1 Receptor Agonists | Body Weight | 87/100Strong | 83/100Positive | 96/100consistent | 26 | ||
| GLP-1 Receptor Agonists | HbA1c | 87/100Strong | 93/100Very Positive | 93/100consistent | 27 | ||
| Diabetes Self-Management Education and Support (DSMES) Programs | Quality of Life Outcomes | 86/100Strong | 85/100Very Positive | 78/100consistent | 10 | ||
| Diabetes Self-Management Education and Support (DSMES) Programs | Fasting Glucose | 86/100Strong | 81/100Positive | 57/100generally_consistent | 8 | ||
| Insulin Delivery Systems | CGM Time in Range | 86/100Strong | 72/100Positive | 73/100generally_consistent | 17 |
Metformin Therapies → HbA1c is supported by 8 studies with consistent findings and strong evidence.
GLP-1 Receptor Agonists → Body Weight is supported by 26 studies with consistent findings and strong evidence.
GLP-1 Receptor Agonists → HbA1c is supported by 27 studies with consistent findings and strong evidence.
Diabetes Self-Management Education and Support (DSMES) Programs → Quality of Life Outcomes is supported by 10 studies with consistent findings and strong evidence.
Diabetes Self-Management Education and Support (DSMES) Programs → Fasting Glucose is supported by 8 studies with generally_consistent findings and strong evidence.
Insulin Delivery Systems → CGM Time in Range is supported by 17 studies with generally_consistent findings and strong evidence.
Each row is a directional intervention–outcome relationship summarized at group level.
| Intervention group | Outcome group | EvidenceScore™ | ImpactScore™ | Consistency | Studies | Action |
|---|---|---|---|---|---|---|
| Metformin Therapies | HbA1c | 88/100Strong | 83/100Positive | 86/100consistent | 8 | |
| GLP-1 Receptor Agonists | Body Weight | 87/100Strong | 83/100Positive | 96/100consistent | 26 | |
| GLP-1 Receptor Agonists | HbA1c | 87/100Strong | 93/100Very Positive | 93/100consistent | 27 | |
| Diabetes Self-Management Education and Support (DSMES) Programs | Quality of Life Outcomes | 86/100Strong | 85/100Very Positive | 78/100consistent | 10 | |
| Diabetes Self-Management Education and Support (DSMES) Programs | Fasting Glucose | 86/100Strong | 81/100Positive | 57/100generally_consistent | 8 | |
| Insulin Delivery Systems | CGM Time in Range | 86/100Strong | 72/100Positive | 73/100generally_consistent | 17 |
Curated collections of evidence organized by strength, topic, and clinical relevance
Relationships with very strong or strong evidence ratings.
These relationships have the most robust evidence bases with high consistency.
Shows where research consensus is strongest and clinical confidence is highest.
Relationships with the highest volume of research.
These areas have attracted the most research attention and replication.
Indicates research priorities and areas of sustained scientific focus.
Relationships with highly consistent results across studies.
Results show strong agreement across different populations and study designs.
Signals reliability and reproducibility of findings.
Evidence for digital health and monitoring technologies.
Includes CGM, mobile apps, telehealth, and digital therapeutics.
Shows emerging evidence for technology-enabled diabetes management.
Evidence for medication and drug interventions.
Includes all pharmaceutical interventions from GLP-1s to insulin regimens.
Core pharmacological evidence base for diabetes treatment.
Evidence for diet, exercise, and behavioral approaches.
Non-pharmacological approaches to diabetes management.
Foundation of first-line diabetes prevention and management strategies.
All major intervention and outcome categories in one place
| Category | Type | Interventions / Outcomes | Evidence Pairs | Strongest Evidence | View |
|---|---|---|---|---|---|
| Diet and Nutrition | intervention | 128 | 217 | Moderate | View category → |
| Medications | intervention | 326 | 694 | Strong | View category → |
| Physical Activity | intervention | 84 | 133 | Moderate | View category → |
| Supplements | intervention | 208 | 441 | Strong | View category → |
| Devices & Technology | intervention | 128 | 215 | Strong | View category → |
| Behavioral & Lifestyle | intervention | 269 | 580 | Strong | View category → |
| Control | intervention | 32 | 34 | Moderate | View category → |
| Procedures | intervention | 38 | 48 | Moderate | View category → |
| Metabolic Health | outcome | 144 | 519 | Strong | View category → |
| Safety | outcome | 80 | 134 | Strong | View category → |
| Clinical Outcomes | outcome | 137 | 508 | Strong | View category → |
| Glycemic Control | outcome | 196 | 569 | Strong | View category → |
| Patient Reported | outcome | 101 | 308 | Strong | View category → |
| Weight & Anthropometrics | outcome | 79 | 171 | Strong | View category → |
| Adherence & Engagement | outcome | 55 | 153 | Strong | View category → |
